From PD-1/PD-L1 to tertiary lymphoid structures: Paving the way for precision immunotherapy in cholangiocarcinoma treatment
Cholangiocarcinoma (CCA) is a highly malignant hepatobiliary tumor characterized by limited treatment options and poor prognosis. The recent rise of immunotherapy has significantly influenced research in this field. This study presents a bibliometric analysis of 416 articles retrieved from the WOSCC...
Saved in:
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2025-12-01
|
| Series: | Human Vaccines & Immunotherapeutics |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/21645515.2024.2444697 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1841558220977471488 |
|---|---|
| author | Fang-Ju Huang Ye-Ying Fang Jia-Ying Wen Jian-Jun Li Qian Lin Qin-Yan Su Yi-Yang Chen Lei Wang Jian-Jia Zeng Bang-Teng Chi Rong-Quan He Di-Yuan Qin Li-Hua Yang Gang Chen |
| author_facet | Fang-Ju Huang Ye-Ying Fang Jia-Ying Wen Jian-Jun Li Qian Lin Qin-Yan Su Yi-Yang Chen Lei Wang Jian-Jia Zeng Bang-Teng Chi Rong-Quan He Di-Yuan Qin Li-Hua Yang Gang Chen |
| author_sort | Fang-Ju Huang |
| collection | DOAJ |
| description | Cholangiocarcinoma (CCA) is a highly malignant hepatobiliary tumor characterized by limited treatment options and poor prognosis. The recent rise of immunotherapy has significantly influenced research in this field. This study presents a bibliometric analysis of 416 articles retrieved from the WOSCC, Wan fang Data, CNKI and VIP databases, spanning contributions from 32 countries, 589 institutions and 3,200 authors. The analysis identified “PD-L1,” “PD-1” and “pembrolizumab” as central research foci, while “immune checkpoint inhibitors,” “tumor immune microenvironment,” “tertiary lymphoid structures” and “durvalumab” emerged as key areas of interest. These findings emphasize the pivotal role of immunotherapy in improving survival outcomes for CCA, and they highlight the significance of tertiary lymphoid structures within the tumor microenvironment as a promising target for future research. This study offers a strategic overview of the evolving landscape of CCA immunotherapy, providing valuable insights to guide future scientific endeavors in this domain. |
| format | Article |
| id | doaj-art-eec97bab270649f1ad59e72ca52056c5 |
| institution | Kabale University |
| issn | 2164-5515 2164-554X |
| language | English |
| publishDate | 2025-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Human Vaccines & Immunotherapeutics |
| spelling | doaj-art-eec97bab270649f1ad59e72ca52056c52025-01-06T09:10:17ZengTaylor & Francis GroupHuman Vaccines & Immunotherapeutics2164-55152164-554X2025-12-0121110.1080/21645515.2024.2444697From PD-1/PD-L1 to tertiary lymphoid structures: Paving the way for precision immunotherapy in cholangiocarcinoma treatmentFang-Ju Huang0Ye-Ying Fang1Jia-Ying Wen2Jian-Jun Li3Qian Lin4Qin-Yan Su5Yi-Yang Chen6Lei Wang7Jian-Jia Zeng8Bang-Teng Chi9Rong-Quan He10Di-Yuan Qin11Li-Hua Yang12Gang Chen13Department of Pathology, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi Zhuang Autonomous Region, P. R. ChinaDepartment of Radiation Oncology, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi Zhuang Autonomous Region, P. R. ChinaDepartment of Radiotherapy, The Second Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi Zhuang Autonomous Region, P. R. ChinaDepartment of General Surgery, The Second Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi Zhuang Autonomous Region, P. R. ChinaDepartment of Pathology, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi Zhuang Autonomous Region, P. R. ChinaDepartment of Pathology, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi Zhuang Autonomous Region, P. R. ChinaDepartment of Pathology, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi Zhuang Autonomous Region, P. R. ChinaDepartment of Pathology, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi Zhuang Autonomous Region, P. R. ChinaDepartment of Pathology, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi Zhuang Autonomous Region, P. R. ChinaDepartment of Pathology, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi Zhuang Autonomous Region, P. R. ChinaDepartment of Medical Oncology, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi Zhuang Autonomous Region, P. R. ChinaDepartment of Computer Science and Technology, School of Computer and Electronic Information, Guangxi University, Nanning, Guangxi Zhuang Autonomous Region, People’s Republic of ChinaDepartment of Medical Oncology, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi Zhuang Autonomous Region, P. R. ChinaDepartment of Pathology, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi Zhuang Autonomous Region, P. R. ChinaCholangiocarcinoma (CCA) is a highly malignant hepatobiliary tumor characterized by limited treatment options and poor prognosis. The recent rise of immunotherapy has significantly influenced research in this field. This study presents a bibliometric analysis of 416 articles retrieved from the WOSCC, Wan fang Data, CNKI and VIP databases, spanning contributions from 32 countries, 589 institutions and 3,200 authors. The analysis identified “PD-L1,” “PD-1” and “pembrolizumab” as central research foci, while “immune checkpoint inhibitors,” “tumor immune microenvironment,” “tertiary lymphoid structures” and “durvalumab” emerged as key areas of interest. These findings emphasize the pivotal role of immunotherapy in improving survival outcomes for CCA, and they highlight the significance of tertiary lymphoid structures within the tumor microenvironment as a promising target for future research. This study offers a strategic overview of the evolving landscape of CCA immunotherapy, providing valuable insights to guide future scientific endeavors in this domain.https://www.tandfonline.com/doi/10.1080/21645515.2024.2444697Cholangiocarcinomaimmunotherapybibliometricsimmune checkpoint inhibitortertiary lymphoid structures |
| spellingShingle | Fang-Ju Huang Ye-Ying Fang Jia-Ying Wen Jian-Jun Li Qian Lin Qin-Yan Su Yi-Yang Chen Lei Wang Jian-Jia Zeng Bang-Teng Chi Rong-Quan He Di-Yuan Qin Li-Hua Yang Gang Chen From PD-1/PD-L1 to tertiary lymphoid structures: Paving the way for precision immunotherapy in cholangiocarcinoma treatment Human Vaccines & Immunotherapeutics Cholangiocarcinoma immunotherapy bibliometrics immune checkpoint inhibitor tertiary lymphoid structures |
| title | From PD-1/PD-L1 to tertiary lymphoid structures: Paving the way for precision immunotherapy in cholangiocarcinoma treatment |
| title_full | From PD-1/PD-L1 to tertiary lymphoid structures: Paving the way for precision immunotherapy in cholangiocarcinoma treatment |
| title_fullStr | From PD-1/PD-L1 to tertiary lymphoid structures: Paving the way for precision immunotherapy in cholangiocarcinoma treatment |
| title_full_unstemmed | From PD-1/PD-L1 to tertiary lymphoid structures: Paving the way for precision immunotherapy in cholangiocarcinoma treatment |
| title_short | From PD-1/PD-L1 to tertiary lymphoid structures: Paving the way for precision immunotherapy in cholangiocarcinoma treatment |
| title_sort | from pd 1 pd l1 to tertiary lymphoid structures paving the way for precision immunotherapy in cholangiocarcinoma treatment |
| topic | Cholangiocarcinoma immunotherapy bibliometrics immune checkpoint inhibitor tertiary lymphoid structures |
| url | https://www.tandfonline.com/doi/10.1080/21645515.2024.2444697 |
| work_keys_str_mv | AT fangjuhuang frompd1pdl1totertiarylymphoidstructurespavingthewayforprecisionimmunotherapyincholangiocarcinomatreatment AT yeyingfang frompd1pdl1totertiarylymphoidstructurespavingthewayforprecisionimmunotherapyincholangiocarcinomatreatment AT jiayingwen frompd1pdl1totertiarylymphoidstructurespavingthewayforprecisionimmunotherapyincholangiocarcinomatreatment AT jianjunli frompd1pdl1totertiarylymphoidstructurespavingthewayforprecisionimmunotherapyincholangiocarcinomatreatment AT qianlin frompd1pdl1totertiarylymphoidstructurespavingthewayforprecisionimmunotherapyincholangiocarcinomatreatment AT qinyansu frompd1pdl1totertiarylymphoidstructurespavingthewayforprecisionimmunotherapyincholangiocarcinomatreatment AT yiyangchen frompd1pdl1totertiarylymphoidstructurespavingthewayforprecisionimmunotherapyincholangiocarcinomatreatment AT leiwang frompd1pdl1totertiarylymphoidstructurespavingthewayforprecisionimmunotherapyincholangiocarcinomatreatment AT jianjiazeng frompd1pdl1totertiarylymphoidstructurespavingthewayforprecisionimmunotherapyincholangiocarcinomatreatment AT bangtengchi frompd1pdl1totertiarylymphoidstructurespavingthewayforprecisionimmunotherapyincholangiocarcinomatreatment AT rongquanhe frompd1pdl1totertiarylymphoidstructurespavingthewayforprecisionimmunotherapyincholangiocarcinomatreatment AT diyuanqin frompd1pdl1totertiarylymphoidstructurespavingthewayforprecisionimmunotherapyincholangiocarcinomatreatment AT lihuayang frompd1pdl1totertiarylymphoidstructurespavingthewayforprecisionimmunotherapyincholangiocarcinomatreatment AT gangchen frompd1pdl1totertiarylymphoidstructurespavingthewayforprecisionimmunotherapyincholangiocarcinomatreatment |